IMB Dx, Inc. (KOSDAQ:461030)
South Korea
· Delayed Price · Currency is KRW 7,150.00
+20.00 (0.28%)
Apr 29, 2026, 3:30 PM KST
IMB Dx Revenue
In the year 2025, IMB Dx had annual revenue of 5.33B KRW with 56.40% growth. IMB Dx had revenue of 1.70B in the quarter ending December 31, 2025, with 168.62% growth.
Revenue
5.33B
Revenue Growth
+56.40%
P/S Ratio
18.81
Revenue / Employee
n/a
Employees
n/a
Market Cap
100.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.33B | 1.92B | 56.40% |
| Dec 31, 2024 | 3.41B | -619.97M | -15.40% |
| Dec 31, 2023 | 4.03B | 1.40B | 53.42% |
| Dec 31, 2022 | 2.62B | 1.39B | 113.34% |
| Dec 31, 2021 | 1.23B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CG Invites | 27.39B |
| Oncocross | 370.46M |
| GeneOne Life Science | 23.04B |
| iNtRON Biotechnology | 5.74B |
| Amicogen | 41.98B |
| ORIENT BIO | 59.09B |
| Vaxcell-Bio Therapeutics | 1.90B |
| ENCell | 5.26B |